Finance

Lists
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
331,90 BRL
+0,65%
(+2,15) 1D
30-сен., 11:31:25 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
121,95 млд
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 BRL
52-wk low
221,72 BRL
Shares outstanding
2,04 млд
No. of employees
32 миң
Mkt. cap
121,95 млд
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 BRL
52-wk low
221,72 BRL
Shares outstanding
2,04 млд
No. of employees
32 миң
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32,5 миң
Founded1887
HeadquartersНью-Йорк, Нью Йорк, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitebms.com
Last report
2026-ж., 30-июл.
Fiscal period
Q2 2026
2,04 USD / 1,60 USD
+27,74%beat
Revenue / Est. (USD)
12,97 млд / 11,74 млд
+10,53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
12,22 млд
12,50 млд
11,49 млд
12,97 млд
Cost of goods sold
3,31 млд
3,51 млд
3,41 млд
3,71 млд
Cost of revenue
3,31 млд
3,51 млд
3,41 млд
3,71 млд
Research and development expenses
2,43 млд
2,56 млд
2,24 млд
2,54 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,79 млд
2,09 млд
1,61 млд
1,82 млд
Operating expense
5,05 млд
5,47 млд
4,28 млд
4,80 млд
Total operating expenses
8,36 млд
8,98 млд
7,69 млд
8,51 млд
Operating income
3,86 млд
3,52 млд
3,80 млд
4,46 млд
Other non operating income
529,00 млн
544,00 млн
125,00 млн
106,00 млн
EBT including unusual items
3,11 млд
1,47 млд
3,24 млд
4,09 млд
EBT excluding unusual items
4,07 млд
3,86 млд
3,65 млд
4,35 млд
Income tax expense
919,00 млн
384,00 млн
561,00 млн
770,00 млн
Effective tax rate
29,51%
26,12%
17,32%
18,84%
Other operating expenses
-
-
-
-
Net income
2,20 млд
1,09 млд
2,68 млд
3,32 млд
Net profit margin
18,01%
8,69%
23,30%
25,57%
Earnings per share
1,63
1,26
1,58
2,04
Interest and investment income
161,00 млн
148,00 млн
104,00 млн
101,00 млн
Interest expense
-482,00 млн
-432,00 млн
-406,00 млн
-403,00 млн
Net interest expenses
-321,00 млн
-284,00 млн
-302,00 млн
-302,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,91 млд
4,54 млд
4,41 млд
5,08 млд
Gain or loss from assets sale
-9,00 млн
-
-34,00 млн
-142,00 млн
AI content may include mistakes. Learn more
Google колдонмолору